



# IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

24-25 MARCH 2024  
TOKYO, JAPAN

an **IPOPI** event

COLLABORATION



SUPPORTED BY





# WI-FI

User: **SCCC\_RoomA**  
Password: **solacity01**



**IPOPI**  
**5<sup>TH</sup> REGIONAL**  
**ASIAN PID MEETING**  
24-25 MARCH 2024  
TOKYO, JAPAN  
an **IPOPI** event

COLLABORATION



SUPPORTED BY



IPOPI.ORG


# Live Translation

## Step 1



Scan QR Code or Go To:  
<https://attend.wordly.ai/join/KPYA-6720>

## Step 2

A screenshot of the Wordly app interface. At the top is the 'wordly' logo in blue. Below it, in pink, is the text 'AI-POWERED INTERPRETATION'. There are two input fields: 'Choose language \*' with 'English (US)' selected, and 'Enter Session ID \*' which is empty. Below these is a 'More options' link and a blue 'Attend' button. A small question mark icon is also visible.

Choose Language  
Click Attend

## Step 3



Read Captions on Device  
Use Headset for Audio

# Asian perspectives on PID diagnostics and screening

Moderators:

Mr Bruce Lim (IPOPI Vice-President)  
Dr Narissara Suratannon (Thailand)



**IPOPI**  
**5<sup>TH</sup> REGIONAL**  
**ASIAN PID MEETING**  
24-25 MARCH 2024  
TOKYO, JAPAN  
an **IPOPI** event

COLLABORATION



SUPPORTED BY



# Specific infectious agents relevant to PID in the Asian region

Prof Surjit Singh | India



IPOPI  
5<sup>TH</sup> REGIONAL  
ASIAN PID MEETING  
24-25 MARCH 2024  
TOKYO, JAPAN  
an IPOPI event

COLLABORATION



SUPPORTED BY



# Specific infectious agents relevant to PID in the Asian region

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event



50 Glorious years of PGIMER

**Dr. Surjit Singh**

**MD; DCH (Lon.); FRCP (Lon.); FRCPCH (Lon.); FAMS**

*Head, Department of Pediatrics, and Chief, Allergy Immunology Unit,  
Advanced Pediatrics Centre, PGIMER, Chandigarh, India*

**WHO Collaborating Centre for Pediatric Immunology (2022-2026)**

**Centre of Excellence, Asia Pacific Society for Immunodeficiencies (2023-2026)**

**President, Asia Pacific Society for Immunodeficiencies (2020-2024)**

**Indian Council of Medical Research Collaborating Centre of Excellence in Pediatric Immunology  
(2023-2028)**

# Why is the Asia-Pacific region so important?

It is home to **2/3<sup>rd</sup>** of the world's  
**population**

India and China together comprise  
**1/3<sup>rd</sup>** of the world's population



# Why is the Asia-Pacific region so different?

Breakthrough infections are more common

Profile of infections is different

Problems associated with:

- i) widespread use of oral polio vaccine
- ii) widespread use of BCG vaccine





**Yu Lung Lau**  
**University of Hong Kong**

# **Chronic granulomatous disease**

> *Pediatr Infect Dis J.* 2008 Mar;27(3):224-30. doi: 10.1097/INF.0b013e31815b494c.

## Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis

Pamela P W Lee<sup>1</sup>, Koon-Wing Chan, Liping Jiang, Tongxin Chen, Chengrong Li, Tsz-Leung Lee, Priscilla H S Mak, Susanna F S Fok, Xiqiang Yang, Yu-Lung Lau

Case Reports > *IDCases.* 2020 Dec 29;23:e01038. doi: 10.1016/j.idcr.2020.e01038.

eCollection 2021.

## BCGitis as the primary manifestation of chronic granulomatous disease

Nastaran Khalili<sup>1 2</sup>, Iraj Mohammadzadeh<sup>3</sup>, Neda Khalili<sup>1 2</sup>, Raúl Jimenez Heredia<sup>4</sup>, Samaneh Zoghi<sup>4 5 6</sup>, Kaan Boztug<sup>4 5 7</sup>, Nima Rezaei<sup>8 9 10</sup>

Multicenter Study > *J Clin Immunol.* 2018 Apr;38(3):260-272. doi: 10.1007/s10875-018-0486-y.

Epub 2018 Mar 20.

## A Cohort of 169 Chronic Granulomatous Disease Patients Exposed to BCG Vaccination: a Retrospective Study from a Single Center in Shanghai, China (2004–2017)

Qinhua Zhou<sup>1</sup>, Xiaoying Hui<sup>1</sup>, Wenjing Ying<sup>1</sup>, Jia Hou<sup>1</sup>, Wenjie Wang<sup>1</sup>, Danru Liu<sup>1</sup>, Ying Wang<sup>1</sup>, Yeheng Yu<sup>1</sup>, Jingyi Wang<sup>1</sup>, Jinqiao Sun<sup>1</sup>, Qian Zhang<sup>2</sup>, Xiaochuan Wang<sup>3</sup>

Multicenter Study > *Front Immunol.* 2021 Feb 25;12:625320. doi: 10.3389/fimmu.2021.625320. eCollection 2021.

## Clinical, Immunological, and Molecular Profile of Chronic Granulomatous Disease: A Multi-Centric Study of 236 Patients From India

Amit Rawat<sup>1</sup>, Pandiarajan Vignesh<sup>1</sup>, Murugan Sudhakar<sup>1</sup>, Madhubala Sharma<sup>1</sup>, Deepti Suri<sup>1</sup>, Ankur Jindal<sup>1</sup>, Anju Gupta<sup>1</sup>, Jitendra Kumar Shandilya<sup>1</sup>, Sathish Kumar Loganathan<sup>1</sup>, Gurjit Kaur<sup>1</sup>, Sanchi Chawla<sup>1</sup>, Pratap Kumar Patra<sup>1</sup>, Alka Khadwal<sup>2</sup>, Biman Saikia<sup>3</sup>, Ranjana Walker Minz<sup>3</sup>, Vaishali Aggarwal<sup>1</sup>, Prasad Taur<sup>4</sup>, Ambreen Pandrowala<sup>4</sup>, Vijaya Gowri<sup>4</sup>, Mukesh Desai<sup>4</sup>, Manasi Kulkarni<sup>5</sup>, Gauri Hule<sup>5</sup>, Umair Bargir<sup>5</sup>, Priyanka Kambli<sup>5</sup>, Manisha Madkaikar<sup>5</sup>, Sagar Bhattad<sup>6</sup>, Chetan Ginigeri<sup>6</sup>, Harish Kumar<sup>6</sup>, Ananthvikas Jayaram<sup>7</sup>, Deenadayalan Munirathnam<sup>8</sup>, Meena Sivasankaran<sup>8</sup>, Revathi Raj<sup>9</sup>, Ramya Uppuluri<sup>9</sup>, Fouzia Na<sup>10</sup>, Biju George<sup>10</sup>, Harsha Prasada Lashkari<sup>11</sup>, Manas Kalra<sup>12</sup>, Anupam Sachdeva<sup>12</sup>, Shishir Seth<sup>13</sup>, Tapas Sabui<sup>14</sup>, Aman Gupta<sup>15</sup>, Karin van Leeuwen<sup>16</sup>, Martin de Boer<sup>16</sup>, Koon Wing Chan<sup>17</sup>, Kohsuke Imai<sup>18 19</sup>, Osamu Ohara<sup>20</sup>, Shigeaki Nonoyama<sup>18</sup>, Yu Lung Lau<sup>17</sup>, Surjit Singh<sup>1</sup>


Mycobacterial disease	No of patients (Organism positive) (n = 44)	%
<b><i>Mycobacterium sp.</i></b>	27 (2, non-tuberculous)	61.3
• Pneumonia	24	54.5
• Lymphadenitis	6	13.6
• Abdominal	2	4.5
• Osteomyelitis	2	4.5
• CNS	1	2.2
• Skin (Lupus vulgaris)	1	2.2
• Disseminated tuberculosis	9	20.4
<b>BCG infection</b>	17	38.6
• Localized BCG adenitis	13	29.5
• Disseminated BCG	4	9

- Infections with mycobacteria have been reported in children with CGD, especially from countries where tuberculosis is endemic and BCG vaccine is given as a routine

# Mycobacterial infections in CGD patients in Hong Kong and China

Study, Year	No. of patients	BCG related complications	Tuberculosis
Lau YL et al, 1998 (Hong Kong)	11	-	<b>6/11 patients (54%)</b> <ul style="list-style-type: none"> <li>All had pulmonary tuberculosis</li> <li>2 had lymph node tuberculosis in addition</li> </ul>
Lee et al, 2008 (China)	17	<b>BCG complications:</b> <ul style="list-style-type: none"> <li>Chronic ulceration, discharge, abnormal scarring at BCG injection: 7</li> <li>BCG adenitis: 4</li> <li>Dissemination: 2</li> </ul>	<b>Tuberculosis: 7</b> <ul style="list-style-type: none"> <li>Culture proven: 6</li> <li>Dissemination: 3</li> <li>Recurrence: 3</li> </ul>
Zhou et al, 2018 (China)	169	<b>130 received vaccination:</b> <ul style="list-style-type: none"> <li>Definitive BCG infection: 17/130 (13.1% )</li> <li>Probable BCG infection: 60/130 (46.2%)</li> <li>No BCG-related disease: 12/130 (9.2%)</li> <li>Unknown status: 41/130 (31.5%)</li> </ul>	

## Common sites of infection in patients with CGD



> [Front Immunol.](https://doi.org/10.3389/fimmu.2021.803763) 2022 Jan 24;12:803763. doi: 10.3389/fimmu.2021.803763. eCollection 2021.

### Phenomic Analysis of Chronic Granulomatous Disease Reveals More Severe Integumentary Infections in X-Linked Compared With Autosomal Recessive Chronic Granulomatous Disease

Timothy Lok-Hin Chiu<sup>1</sup>, Daniel Leung<sup>1</sup>, Koon-Wing Chan<sup>1</sup>, Hok Man Yeung<sup>1</sup>, Chung-Yin Wong<sup>1</sup>, Huawei Mao<sup>2</sup>, Jianxin He<sup>3</sup>, Pandiarajan Vignesh<sup>4</sup>, Weiling Liang<sup>5</sup>, Woei Kang Liew<sup>6</sup>, Li-Ping Jiang<sup>7</sup>, Tong-Xin Chen<sup>8</sup>, Xiang-Yuan Chen<sup>9</sup>, Yin-Bo Tao<sup>9</sup>, Yong-Bin Xu<sup>10</sup>, Hsin-Hui Yu<sup>11</sup>, Alta Terblanche<sup>12</sup>, David Christopher Lung<sup>13</sup>, Cheng-Rong Li<sup>14</sup>, Jing Chen<sup>15</sup>, Man Tian<sup>16</sup>, Brian Eley<sup>17</sup>, Xingtian Yang<sup>1</sup>, Jing Yang<sup>1</sup>, Wen Chin Chiang<sup>6</sup>, Bee Wah Lee<sup>18, 19</sup>, Deepti Suri<sup>4</sup>, Amit Rawat<sup>4</sup>, Anju Gupta<sup>4</sup>, Surjit Singh<sup>4</sup>, Wilfred Hing Sang Wong<sup>1</sup>, Gilbert T Chua<sup>1</sup>, Jaime Sou Da Rosa Duque<sup>1</sup>, Kai-Ning Cheong<sup>20</sup>, Patrick Chun-Yin Chong<sup>21</sup>, Marco Hok-Kung Ho<sup>21</sup>, Tsz-Leung Lee<sup>20</sup>, Wanling Yang<sup>1</sup>, Pamela P Lee<sup>1</sup>, Yu Lung Lau<sup>1</sup>

## Chandigarh, North India



**Amit Rawat**



**Vignesh Pandiarajan**

# Chronic granulomatous disease

Multicenter Study > Front Immunol. 2021 Feb 25;12:625320. doi: 10.3389/fimmu.2021.625320. eCollection 2021.

## Clinical, Immunological, and Molecular Profile of Chronic Granulomatous Disease: A Multi-Centric Study of 236 Patients From India

Amit Rawat<sup>1</sup>, Pandiarajan Vignesh<sup>1</sup>, Murugan Sudhakar<sup>1</sup>, Madhubala Sharma<sup>1</sup>, Deepti Suri<sup>1</sup>, Ankur Jindal<sup>1</sup>, Anju Gupta<sup>1</sup>, Jitendra Kumar Shandilya<sup>1</sup>, Sathish Kumar Loganathan<sup>1</sup>, Gurjit Kaur<sup>1</sup>, Sanchi Chawla<sup>1</sup>, Pratap Kumar Patra<sup>1</sup>, Alka Khadwal<sup>2</sup>, Biman Saikia<sup>3</sup>, Ranjana Walker Minz<sup>3</sup>, Vaishali Aggarwal<sup>1</sup>, Prasad Taur<sup>4</sup>, Ambreen Pandrowala<sup>4</sup>, Vijaya Gowri<sup>4</sup>, Mukesh Desai<sup>4</sup>, Manasi Kulkarni<sup>5</sup>, Gauri Hule<sup>5</sup>, Umair Bargir<sup>5</sup>, Priyanka Kambli<sup>5</sup>, Manisha Madkaikar<sup>5</sup>, Sagar Bhattad<sup>6</sup>, Chetan Ginigeri<sup>6</sup>, Harish Kumar<sup>6</sup>, Ananthvikas Jayaram<sup>7</sup>, Deenadayalan Munirathnam<sup>8</sup>, Meena Sivasankaran<sup>8</sup>, Revathi Raj<sup>9</sup>, Ramya Uppuluri<sup>9</sup>, Fouzia Na<sup>10</sup>, Biju George<sup>10</sup>, Harsha Prasada Lashkari<sup>11</sup>, Manas Kalra<sup>12</sup>, Anupam Sachdeva<sup>12</sup>, Shishir Seth<sup>13</sup>, Tapas Sabui<sup>14</sup>, Aman Gupta<sup>15</sup>, Karin van Leeuwen<sup>16</sup>, Martin de Boer<sup>16</sup>, Koon Wing Chan<sup>17</sup>, Kohsuke Imai<sup>18</sup>, Osamu Ohara<sup>20</sup>, Shigeaki Nonoyama<sup>18</sup>, Yu Lung Lau<sup>17</sup>, Surjit Singh<sup>1</sup>

> J Clin Immunol. 2017 Apr;37(3):319-328. doi: 10.1007/s10875-017-0382-x. Epub 2017 Mar 22.

## Infection Profile in Chronic Granulomatous Disease: a 23-Year Experience from a Tertiary Care Center in North India




Amit Rawat<sup>1</sup>, Pandiarajan Vignesh<sup>2</sup>, Avinash Sharma<sup>2</sup>, Jitendra K Shandilya<sup>2</sup>, Madhubala Sharma<sup>2</sup>, Deepti Suri<sup>2</sup>, Anju Gupta<sup>2</sup>, Vikas Gautam<sup>3</sup>, Pallab Ray<sup>3</sup>, Shivaprakash M Rudramurthy<sup>3</sup>, Arunaloke Chakrabarti<sup>3</sup>, Kohsuke Imai<sup>4</sup>, Shigeaki Nonoyama<sup>4</sup>, Osamu Ohara<sup>5</sup>, Yu L Lau<sup>6</sup>, Surjit Singh<sup>2</sup>

- Apart from signature organisms such as *Aspergillus* sp. and *Staphylococcus* sp., a **high incidence of mycobacterial infections (18.5%)** was documented in India
- Pulmonary infection due to ***Mucor* sp.** was documented in 2 patients
- Unusual bacteria documented with pneumonia include

***Chryseobacterium gleum*, *Citrobacter* sp., and *Francisella noatuensis***

# Tuberculosis and Bacillus Calmette–Guérin Disease in Patients with Chronic Granulomatous Disease: an Experience from a Tertiary Care Center in North India

Pandiarajan Vignesh<sup>1</sup>, Archan Sil<sup>2</sup>, Ridhima Aggarwal<sup>2</sup>, Wrik Laha<sup>2</sup>, Sanjib Mondal<sup>2</sup>, Manpreet Dhaliwal<sup>2</sup>, Saniya Sharma<sup>2</sup>, Rakesh Kumar Pilania<sup>3</sup>, Ankur Kumar Jindal<sup>2</sup>, Deepti Suri<sup>2</sup>, Sunil Sethi<sup>4</sup>, Amit Rawat<sup>5</sup>, Surjit Singh<sup>3</sup>



> Clin Immunol. 2023 Oct;255:109769. doi: 10.1016/j.clim.2023.109769. Epub 2023 Sep 11.

## Infections due to Salmonella sp. in children with chronic granulomatous disease: Our experience from North India

Suprit Basu <sup>1</sup>, Pandiarajan Vignesh <sup>2</sup>, K Prithviraj <sup>1</sup>, Pallavi L Nadig <sup>1</sup>, Aravind Sekar <sup>3</sup>, Amit Rawat <sup>1</sup>

- 3/99 patients had blood stream infections with Salmonella sp.:  
1 patient had severe typhoidal sepsis despite cotrimoxazole prophylaxis
- **Vaccination with killed typhoidal vaccines should be given to children with CGD to avoid typhoidal bacteremia**

> Pediatr Infect Dis J. 2023 Jul 1;42(7):e243-e245. doi: 10.1097/INF.0000000000003927. Epub 2023 Mar 31.

## Stenotrophomonas maltophilia : An Emerging Pathogen in Chronic Granulomatous Disease

Ridhima Aggarwal <sup>1</sup>, Sanjib Mondal <sup>1</sup>, Archana Angrup <sup>2</sup>, Pandiarajan Vignesh <sup>3</sup>, Amit Rawat <sup>3</sup>

Case Reports > J Clin Immunol. 2021 May;41(4):814-816. doi: 10.1007/s10875-020-00939-8.

Epub 2021 Jan 16.

## Aspergillus fumigatus Skull Bone Osteomyelitis and Native Valve Endocarditis in a Young Boy: an Unusual Presentation of Chronic Granulomatous Disease

Gummadi Anjani <sup>1</sup>, Ankur Kumar Jindal <sup>2</sup>, Ashwini Prithvi <sup>1</sup>, Harsimran Kaur <sup>3</sup>, Madhubala Sharma <sup>1</sup>, Sanjeev Naganur <sup>4</sup>, Pandiarajan Vignesh <sup>1</sup>, Amit Rawat <sup>1</sup>, Surjit Singh <sup>1</sup>

Case Reports > J Clin Immunol. 2021 Feb;41(2):486-490. doi: 10.1007/s10875-020-00919-y.

Epub 2020 Nov 20.

## Infection Due to Serratia sp. in Chronic Granulomatous Disease-Is the Incidence Low in Tropical Countries?

Dharmagat Bhattarai <sup>1</sup>, Aman Gupta <sup>1</sup>, Pandiarajan Vignesh <sup>2</sup>, Hitender Rao <sup>1</sup>, Archana Angrup <sup>3</sup>, Amit Rawat <sup>1</sup>

## Endemic infections in Southeast Asia provide new insights to the phenotypic spectrum of primary immunodeficiency disorders

Pamela Pui-Wah Lee<sup>1</sup>, Yu-Lung Lau

eCollection 2020 Mar.

## Current status and prospects of primary immunodeficiency diseases in Asia

Rakesh Kumar Pilania<sup>1</sup>, Himanshi Chaudhary<sup>1</sup>, Ankur Kumar Jindal<sup>1</sup>, Amit Rawat<sup>1</sup>, Surjit Singh<sup>1</sup>

### Melioidosis in CGD

Year	Locality	Gender	CGD type	Age at the time of melioidosis	Presentation
1971 (Tarlow) <sup>33</sup>	Caucasian residing in Singapore	Male	Unknown	2 years	Fever, irritability, meningism Membrane formation in pharynx, culture positive for <i>B. pseudomallei</i> Toe and finger abscesses, bone curettings positive for <i>B. pseudomallei</i>
Present report	Hong Kong	Male	X-CGD	40 years	Fulminant pulmonary melioidosis and systemic diseases
Present report	Singapore	Male	X-CGD	12 years	Fever, acute encephalopathy, right middle lobe pneumonia, <i>B. pseudomallei</i> bacteremia, multi-organ failure Younger brother died of <i>B. pseudomallei</i> septicemia at 2 years

- **Chromobacterium violaceum** has been reported as signature organism for CGD in many Asian countries
- Initially reported in patients from Malaysia and later from Vietnam, Thailand, Sri Lanka, India, Hong Kong SAR and Taiwan
- Mortality rates as high as 50% have been reported

# Common infections in CGD cohorts worldwide

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event

Organisms isolated	Winkelstein et al, 2000, USA (n=368)	Van den Berg et al, 2009, European cohort (n=429)	Fattahi et al, 2011, Iran; (n=93)	Oliveira-Junior et al, 2015, LASID Registry; (n=71)	Marcino et al, 2015, USA; (n=268)	Blancas-Galicia et al, 2020, Mexico; (n=93)	Rawat et al, 2021, India; (n=236)
<i>Staphylococcus aureus</i>	12%	<b>30%</b>	7.5%	20.3%	<b>33%</b>	<b>53.7%</b>	<b>20.3%</b>
<i>Pseudomonas</i> sp	3%	2%	1.1%			19.3%	9.4%
<i>Burkholderia</i> sp	8%	1%			17%	10.7%	8.9%
Gram negative septicemia	<b>18%</b>	16% (Salmonella sp)	10.7%	<b>25.1%</b>	<b>33%</b>	<b>54.8%</b>	13.5%
<i>Aspergillus fumigatus</i>	<b>41%</b>	<b>26%</b>	<b>18.3%</b>	13%	<b>46%</b>	32.3%	<b>16.9%</b>
Mycobacteria	4%	8%	<b>55.9%</b>	<b>30.4%</b>		<b>53.4%</b>	<b>18.5%</b>

# **X-linked agammaglobulinemia**




**Amit Rawat**



**Ankur Jindal**

**Chandigarh,  
North India**



Multicenter Study > *Front Immunol.* 2021 Jan 15;11:612323. doi: 10.3389/fimmu.2020.612323. eCollection 2020.

## Clinical and Genetic Profile of X-Linked Agammaglobulinemia: A Multicenter Experience From India

Amit Rawat <sup>1</sup>, Ankur Kumar Jindal <sup>1</sup>, Deepti Suri <sup>1</sup>, Pandiarajan Vignesh <sup>1</sup>, Anju Gupta <sup>1</sup>, Biman Saikia <sup>2</sup>, Ranjana W Minz <sup>2</sup>, Aaqib Zaffar Banday <sup>1</sup>, Rahul Tyagi <sup>1</sup>, Kanika Arora <sup>1</sup>, Vibhu Joshi <sup>1</sup>, Sanjib Mondal <sup>1</sup>, Jitendra Kumar Shandilya <sup>1</sup>, Madhubala Sharma <sup>1</sup>, Mukesh Desai <sup>3</sup>, Prasad Taur <sup>3</sup>, Ambreen Pandrowala <sup>4</sup>, Vijaya Gowri <sup>3</sup>, Sneha Sawant-Desai <sup>5</sup>, Maya Gupta <sup>5</sup>, Aparna Dhondi Dalvi <sup>5</sup>, Manisha Madkaikar <sup>5</sup>, Amita Aggarwal <sup>6</sup>, Revathi Raj <sup>7</sup>, Ramya Uppuluri <sup>7</sup>, Sagar Bhattad <sup>8</sup>, Ananthvikas Jayaram <sup>9</sup>, Harsha Prasad Lashkari <sup>10</sup>, Liza Rajasekhar <sup>11</sup>, Deenadayalan Munirathnam <sup>12</sup>, Manas Kalra <sup>13</sup>, Anuj Shukla <sup>14</sup>, Ruchi Saka <sup>1</sup>, Rajni Sharma <sup>1</sup>, Ravinder Garg <sup>1</sup>, Kohsuke Imai <sup>15</sup>, Shigeaki Nonoyama <sup>16</sup>, Osamu Ohara <sup>17</sup>, Pamela P Lee <sup>18</sup>, Koon Wing Chan <sup>18</sup>, Yu-Lung Lau <sup>18</sup>, Surjit Singh <sup>1</sup>

- *Pseudomonas aeruginosa*, followed by *Streptococcus pneumoniae*, *Staphylococcus aureus* and *Klebsiella pneumoniae* were the most common organisms
- While *Pseudomonas aeruginosa* is not a signature organism for XLA patients, it was noted that patients with XLA who have had episodes of neutropenia are at increased risk of *Pseudomonas* sepsis

# Common infections in XLA cohorts worldwide

IPOPI 5<sup>TH</sup> RI

IPOPI event

Author	Common infections
Rawat et al. (India), 2021, (n=145)	<i>Pseudomonas aeruginosa</i> (overall) Giardia (diarrhea)
Yeh et al. (Taiwan), 2020, (n=29)	<i>Pseudomonas aeruginosa</i> (overall)
Lougaris et al. (Italy), 2020, (n=168)	<i>Hemophilus influenzae</i> followed by <i>Streptococcus pneumoniae</i>
Aadam et al. (North Africa), 2016, (n=50)	<i>Pseudomonas aeruginosa</i> (overall)
García et al. , (Mexico), 2016, (n=26)	<i>Pseudomonas sp.</i> (overall)
Winkelstein et al. (USA), 2006, (n=201)	Pneumococcus (pneumonia) Giardia (diarrhea) Pseudomonas (sepsis)

## **Meningoencephalitis in primary antibody deficiency: Our experience from northwest India**

Ankur Kumar Jindal <sup>1</sup>, Himanshi Chaudhary <sup>2</sup>, Rahul Tyagi <sup>2</sup>, Amit Rawat <sup>2</sup>, Deepti Suri <sup>2</sup>,  
Pratap Kumar Patra <sup>2</sup>, Kanika Arora <sup>2</sup>, Sanchi Chawla <sup>2</sup>, Sameer Vyas <sup>3</sup>, Munish Arora <sup>2</sup>,  
Ridhima Aggarwal <sup>2</sup>, Suprit Basu <sup>2</sup>, Reema Bansal <sup>4</sup>, Man Updesh Singh Sachdeva <sup>5</sup>, Anju Gupta <sup>2</sup>,  
Vignesh Pandiarajan <sup>2</sup>, Naveen Sankhyan <sup>6</sup>, Renu Suthar <sup>6</sup>, Jitendra Kumar Sahu <sup>6</sup>, Mini Singh <sup>7</sup>,  
Reeta Mani <sup>8</sup>, Rajni Sharma <sup>2</sup>, Ruchi Saka <sup>2</sup>, Kohsuke Imai <sup>9</sup>, Osamu Ohara <sup>10</sup>,  
Shigeaki Nonoyama <sup>11</sup>, Lennart Hammarström <sup>12</sup>, Koon Wing Chan <sup>13</sup>, Yu Lung Lau <sup>13</sup>,  
Surjit Singh <sup>2</sup>

- **Meningoencephalitis is usually caused by enteroviruses (e.g., echovirus, coxsackievirus, and poliovirus)**
- 13/135 patients had meningoencephalitis (5 with XLA, 7 with CVID and 1 NEMO defect)
- Herpes simplex virus, Cytomegalovirus, and Streptococcus pneumoniae were isolated in 1 patient each
- Eight patients in the present series have died, 3 have recovered with varying degrees of neurological sequelae and 2 patients are showing gradual recovery

## Infections With Enterohepatic Non-*H. pylori* *Helicobacter* Species in X-Linked Agammaglobulinemia: Clinical Cases and Review of the Literature

Carolina Romo-Gonzalez,<sup>1</sup> Juan Carlos Bustamante-Ogando,<sup>2</sup> Marco Antonio Yamazaki-Nakashimada,<sup>3</sup>

Francisco Aviles-Jimenez,<sup>4</sup> Francisco Otero-Mendoza,<sup>5</sup> Francisco Javier Espinosa-Rosales,<sup>6</sup>

Sara Elva Espinosa-Padilla,<sup>2</sup> Selma Cecilia Scheffler Mendoza,<sup>3</sup> Carola Durán-McKinster,<sup>7</sup>

Maria Teresa García-Romero,<sup>7</sup> Marimar Saez-de-Ocariz,<sup>7</sup> and Gabriela Lopez-Herrera<sup>2,\*</sup>



- Of 21 cases, *Helicobacter cinaedi* was present in 8 cases and *Helicobacter bilis* in 8
- Other species included *H. fennelliae*, *H. equorum*, *H. canis* and *H. canadiensis*
- Infections in these patients were frequently associated with cellulitis that progressed to sepsis and, in some cases, to pyoderma gangrenosum-like ulcers or osteomyelitis
- Cholangitis, abdominal abscess, and pleurisy was reported in 1 case each



**Kuala Lumpur, Malaysia**

**Intan Hakimah Ismail**

## Clinical features and mutational analysis of X-linked agammaglobulinemia patients in Malaysia

Chai Teng Chear <sup>1</sup>, Intan Hakimah Ismail <sup>2</sup>, Kwai Cheng Chan <sup>3</sup>, Lokman Mohd Noh <sup>4</sup>, Asiah Kassim <sup>4</sup>, Amir Hamzah Abdul Latiff <sup>5</sup>, Sandeep Singh Gill <sup>6</sup>, Nazatul Haslina Ramly <sup>4</sup>, Kah Kee Tan <sup>7</sup>, Charlotte Sundaraj <sup>8</sup>, Chong Ming Choo <sup>9</sup>, Sharifah Adlena Syed Mohamed <sup>10</sup>, Mohd Farid Baharin <sup>1</sup>, Amelia Suhana Zamri <sup>1</sup>, Sharifah Nurul Husna Syed Yahya <sup>1</sup>, Saharuddin Bin Mohamad <sup>11 12</sup>, Adiratna Mat Ripen <sup>1</sup>



Ulcerative skin lesion of a patient with X-linked agammaglobulinemia (XLA) due to *Helicobacter* sp. infection

# **Mendelian susceptibility to mycobacterial disease (MSMD)**

# MSMD

- Increased susceptibility to intracellular pathogens like mycobacteria (including *Mycobacterium bovis*, nontuberculous mycobacteria), *Salmonella* sp., fungi and parasites (e.g. *Leishmania*)





**Mukesh Desai**



**Manisha Madkaikar**

**Mumbai,  
Western India**

> Front Immunol. 2021 Feb 25;12:631298. doi: 10.3389/fimmu.2021.631298. eCollection 2021.

## Clinical and Molecular Findings in Mendelian Susceptibility to Mycobacterial Diseases: Experience From India

Prasad D Taur<sup>1</sup>, Vijaya Gowri<sup>1</sup>, Ambreen Abdulwahab Pandrowala<sup>1</sup>, Vaishnavi V Iyengar<sup>1</sup>, Akshaya Chougule<sup>1</sup>, Zainab Golwala<sup>1</sup>, Shraddha Chandak<sup>1</sup>, Reepa Agarwal<sup>1</sup>, Purva Keni<sup>1</sup>, Neha Dighe<sup>1</sup>, Minnie Bodhanwala<sup>1</sup>, Shakuntala Prabhu<sup>1</sup>, Biju George<sup>2</sup>, N A Fouzia<sup>2</sup>, Eunice Sindhuvi Edison<sup>2</sup>, Arun Kumar Arunachalam<sup>2</sup>, Manisha Rajan Madkaikar<sup>3</sup>, Aparna Dhondi Dalvi<sup>3</sup>, Reetika Malik Yadav<sup>3</sup>, Umair Ahmed Bargir<sup>3</sup>, Priyanka Madhav Kambli<sup>3</sup>, Amit Rawat<sup>4</sup>, Jhumki Das<sup>4</sup>, Vibhu Joshi<sup>4</sup>, Rakesh Kumar Pilania<sup>4</sup>, Ankur Kumar Jindal<sup>4</sup>, Sunil Bhat<sup>5</sup>, Sagar Bhattad<sup>6</sup>, Jeelson Unni<sup>6</sup>, Nita Radhakrishnan<sup>7</sup>, Revathi Raj<sup>8</sup>, Ramya Uppuluri<sup>8</sup>, Shivani Patel<sup>8</sup>, Harsha Prasada Lashkari<sup>9</sup>, Amita Aggarwal<sup>10</sup>, Manas Kalra<sup>11</sup>, Zarir Udwadia<sup>12</sup>, Vibha Sanjay Bafna<sup>13</sup>, Tarun Kanade<sup>14</sup>, Anne Puel<sup>15 16 17</sup>, Jacinta Bustamante<sup>15 16 17 18</sup>, Jean Laurent Casanova<sup>15 16 17 19</sup>, Mukesh M Desai<sup>1</sup>

Review

> Expert Rev Clin Immunol. 2021 Oct;17(10):1103-1120.


doi: 10.1080/1744666X.2021.1956314.

## An updated review on Mendelian susceptibility to mycobacterial diseases- a silver jubilee celebration of its first genetic diagnosis


Jhumki Das<sup>1</sup>, Aaqib Zaffar Banday<sup>1</sup>, Jitendra Shandilya<sup>1</sup>, Madhubala Sharma<sup>1</sup>, Pandiarajan Vignesh<sup>1</sup>, Amit Rawat<sup>1</sup>

- All patients (n=55) had mycobacterial disease
- **MTB complex (96%) and NTM (4%)**
- Multisystem involvement with mycobacteria was the commonest followed by lymph node involvement, tubercular osteomyelitis, pulmonary, skin, and CNS involvement in decreasing order of frequency
- **36% of patients in the cohort were infected with more than one organism**

Site of involvement  
with mycobacterium



Spectrum of *micro-organisms* other than *Mycobacterium*



Case Reports > Indian J Tuberc. 2021 Apr;68(2):292-297. doi: 10.1016/j.ijtb.2020.07.027.

Epub 2020 Jul 30.

## Clinical and immunological profile of children with Mendelian Susceptibility to Mycobacterial Diseases (MSMD) from an Indian tertiary care hospital

C K Indumathi<sup>1</sup>, Jacinta Bustamante<sup>2</sup>

### 4 children with mycobacterial disease

- 3 had M. bovis infection
- 1 had M. chelonae infection
- 1 also had S. typhimurium infection

Case Reports > J Clin Immunol. 2015 Jul;35(5):459-62. doi: 10.1007/s10875-015-0173-1.

Epub 2015 Jun 9.

## Disseminated Mycobacterium avium complex infection in a child with partial dominant interferon gamma receptor 1 deficiency in India

Varun K Sharma<sup>1</sup>, Gautham Pai, Caroline Deswarte, Rakesh Lodha, Sarman Singh, Liew Woei Kang, Chong Chia Yin, Jean-Laurent Casanova, Jacinta Bustamante, Sushil K Kabra

> Pediatr Allergy Immunol. 2023 Sep;34(9):e14027. doi: 10.1111/pai.14027.

## Disseminated Mycobacterium fortuitum infection in a young girl with IFN- $\gamma$ R1 defect masquerading as histiocytosis

Archan Sil<sup>1</sup>, Suprit Basu<sup>1</sup>, Jhumki Das<sup>1</sup>, Sunil Sethi<sup>2</sup>, Debajyoti Chatterjee<sup>3</sup>, Pandiarajan Vignesh<sup>1</sup>, Deepti Suri<sup>1</sup>, Ankur Kumar Jindal<sup>1</sup>

Heliyon. 2023 Dec; 9(12): e22632.

PMCID: PMC10696184

Published online 2023 Nov 25. doi: [10.1016/j.heliyon.2023.e22632](https://doi.org/10.1016/j.heliyon.2023.e22632)

PMID: [3805843](https://pubmed.ncbi.nlm.nih.gov/3805843/)


## Adult-onset Mendelian Susceptibility to Mycobacterial Diseases: A case report and systematic literature review

Yang Yang,<sup>a,1</sup> Lu Xia,<sup>a,1</sup> and Shuihua Lu<sup>b,\*</sup>

# Severe combined immunodeficiency (SCID)



**Yu Lung Lau**



**Pamela Lee**

**Hong Kong**

## **Molecular diagnosis of severe combined immunodeficiency--identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children**

Pamela P W Lee <sup>1</sup>, Koon-Wing Chan, Tong-Xin Chen, Li-Ping Jiang, Xiao-Chuan Wang, Hua-Song Zeng, Xiang-Yuan Chen, Woei-Kang Liew, Jing Chen, Kit-Man Chu, Lee-Lee Chan, Lynette Shek, Anselm C W Lee, Hsin-Hui Yu, Qiang Li, Chen-Guang Xu, Geraldine Sultan-Ugdoracion, Zarina Abdul Latiff, Amir Hamzah Abdul Latiff, Orathai Jirapongsananuruk, Marco H K Ho, Tsz-Leung Lee, Xi-Qiang Yang, Yu-Lung Lau

- **Pneumonia and chronic diarrhea were the most common infections**
- **BCG complications seen in 10/42 patients (23.8 %):** abscess (n = 6), axillary adenopathy (n = 3), disseminated BCG (n = 3)

- 2 had disseminated Cytomegalovirus disease
- 2 had Pneumocystis jiroveci pneumonia
- 1 had Pulmonary aspergillosis
- 12 (28.6%) had persistent oral candidiasis
- 2 had candidemia



**Vignesh Pandiarajan**




**Amit Rawat**

**Chandigarh,  
North India**

## Clinical, Immunological, and Molecular Features of Severe Combined Immune Deficiency: A Multi-Institutional Experience From India

Pandiarajan Vignesh<sup>1</sup>, Amit Rawat<sup>1</sup>, Rajni Kumrah<sup>1</sup>, Ankita Singh<sup>1</sup>, Anjani Gummadi<sup>1</sup>, Madhubala Sharma<sup>1</sup>, Anit Kaur<sup>1</sup>, Johnson Nameirakpam<sup>1</sup>, Ankur Jindal<sup>1</sup>, Deepti Suri<sup>1</sup>, Anju Gupta<sup>1</sup>, Alka Khadwal<sup>2</sup>, Biman Saikia<sup>3</sup>, Ranjana Walker Minz<sup>3</sup>, Kaushal Sharma<sup>1</sup>, Mukesh Desai<sup>4</sup>, Prasad Taur<sup>4</sup>, Vijaya Gowri<sup>4</sup>, Ambreen Pandrowala<sup>5</sup>, Aparna Dalvi<sup>6</sup>, Neha Jodhawat<sup>6</sup>, Priyanka Kambli<sup>6</sup>, Manisha Rajan Madkaikar<sup>6</sup>, Sagar Bhattad<sup>7</sup>, Stalin Ramprakash<sup>8</sup>, Raghuram Cp<sup>8</sup>, Ananthvikas Jayaram<sup>9</sup>, Meena Sivasankaran<sup>1</sup>, Deenadayalan Munirathnam<sup>10</sup>, Sarath Balaji<sup>11</sup>, Aruna Rajendran<sup>11</sup>, Amita Aggarwal<sup>12</sup>, Komal Singh<sup>12</sup>, Fouzia Na<sup>13</sup>, Biju George<sup>13</sup>, Ankit Mehta<sup>14</sup>, Harsha Prasada Lashkari<sup>15</sup>, Ramya Uppuluri<sup>16</sup>, Revathi Raj<sup>16</sup>, Sandip Bartakke<sup>17</sup>, Kirti Gupta<sup>18</sup>, Sreejesh Sreedharanunni<sup>19</sup>, Yumi Ogura<sup>20</sup>, Tamaki Kato<sup>20</sup>, Kohsuke Imai<sup>20 21</sup>, Koon Wing Chan<sup>22</sup>, Daniel Leung<sup>22</sup>, Osamu Ohara<sup>23</sup>, Shigeaki Nonoyama<sup>20</sup>, Michael Hershtfeld<sup>24</sup>, Yu-Lung Lau<sup>22</sup>, Surjit Singh<sup>1</sup> **N=277**

- Opportunistic infections were the presenting manifestation in most patients
- These included pneumonia (82%), diarrhea (43.7%), oral thrush (18.4%), BCG site ulceration (17%), otitis media (12.6%), and meningitis (4%)






### BCG site ulceration and pus discharge


- Blood culture proven septicemia: 63 (23%)
- Disseminated CMV infection: 23 (8.3%)
- CMV retinitis: 6 (0.02%)
- Intestinal lymphangiectasia due to CMV was noted on autopsy of a child with X-linked SCID
- Prolonged excretion of vaccine-derived poliovirus in a child with leaky SCID

# Clinical, Immunological, and Molecular Features of Severe Combined Immune Deficiency: A Multi-Institutional Experience From India

Pandiarajan Vignesh <sup>1</sup>, Amit Rawat <sup>1</sup>, Rajni Kumrah <sup>1</sup>, Ankita Singh <sup>1</sup>, Anjani Gummadi <sup>1</sup>, Madhubala Sharma <sup>1</sup>, Anit Kaur <sup>1</sup>, Johnson Nameirakpam <sup>1</sup>, Ankur Jindal <sup>1</sup>, Deepti Suri <sup>1</sup>, Anju Gupta <sup>1</sup>, Alka Khadwal <sup>2</sup>, Biman Saikia <sup>3</sup>, Ranjana Walker Minz <sup>3</sup>, Kaushal Sharma <sup>1</sup>, Mukesh Desai <sup>4</sup>, Prasad Taur <sup>4</sup>, Vijaya Gowri <sup>4</sup>, Ambreen Pandrowala <sup>5</sup>, Aparna Dalvi <sup>6</sup>, Neha Jodhawat <sup>6</sup>, Priyanka Kambli <sup>6</sup>, Manisha Rajan Madkaikar <sup>6</sup>, Sagar Bhattad <sup>7</sup>, Stalin Ramprakash <sup>8</sup>, Raghuram Cp <sup>8</sup>, Ananthvikas Jayaram <sup>9</sup>, Meena Sivasankaran <sup>10</sup>, Deenadayalan Munirathnam <sup>10</sup>, Sarath Balaji <sup>11</sup>, Aruna Rajendran <sup>11</sup>, Amita Aggarwal <sup>12</sup>, Komal Singh <sup>12</sup>, Fouzia Na <sup>13</sup>, Biju George <sup>13</sup>, Ankit Mehta <sup>14</sup>, Harsha Prasada Lashkari <sup>15</sup>, Ramya Uppuluri <sup>16</sup>, Revathi Raj <sup>16</sup>, Sandip Bartakke <sup>17</sup>, Kirti Gupta <sup>18</sup>, Sreejesh Sreedharanunni <sup>19</sup>, Yumi Ogura <sup>20</sup>, Tamaki Kato <sup>20</sup>, Kohsuke Imai <sup>20</sup> <sup>21</sup>, Koon Wing Chan <sup>22</sup>, Daniel Leung <sup>22</sup>, Osamu Ohara <sup>23</sup>, Shigeaki Nonoyama <sup>20</sup>, Michael Hershfield <sup>24</sup>, Yu-Lung Lau <sup>22</sup>, Surjit Singh <sup>1</sup>



**Mumbai,  
Western India**



**Mukesh Desai**



**Manisha Madkaikar**

## Clinical, Immunological, and Molecular Findings in 57 Patients With Severe Combined Immunodeficiency (SCID) From India

Jahnvi Aluri<sup>1</sup>, Mukesh Desai<sup>2</sup>, Maya Gupta<sup>1</sup>, Aparna Dalvi<sup>1</sup>, Antony Terance<sup>3</sup>, Sergio D Rosenzweig<sup>4</sup>, Jennifer L Stoddard<sup>4</sup>, Julie E Niemela<sup>4</sup>, Vasundhara Tamankar<sup>5</sup>, Snehal Mhatre<sup>1</sup>, Umair Bargir<sup>1</sup>, Manasi Kulkarni<sup>1</sup>, Nitin Shah<sup>6</sup>, Amita Aggarwal<sup>7</sup>, Harsha Prasada Lashkari<sup>8</sup>, Vidya Krishna<sup>9</sup>, Geeta Govindaraj<sup>10</sup>, Manas Kalra<sup>11</sup>, Manisha Madkaikar<sup>1</sup>

- Most common clinical manifestations were **pneumonia (66%), failure to thrive (60%), chronic diarrhea (35%), gastrointestinal infection (21%), oral candidiasis (21%) and BCG-osis (12%)**

### Bacteria:

- *Staphylococcus aureus* ( $n = 2$ )
- *Klebsiella pneumoniae* ( $n = 8$ )
- *Pseudomonas aeruginosa* ( $n = 4$ )
- *Burkholderia sp.* ( $n = 1$ )
- *Chryseobacterium sp.* ( $n = 1$ )

### Viruses:

- Rotavirus ( $n = 1$ )
- Cytomegalovirus ( $n = 2$ )
- Rubella ( $n = 1$ )
- RSV ( $n = 1$ )
- Varicella ( $n = 1$ )

### Fungi:

- *Pneumocystis jiroveci* ( $n = 1$ )

# Leukocyte adhesion deficiency (LAD)

## Clinical and Genetic Spectrum of a Large Cohort of Patients With Leukocyte Adhesion Deficiency Type 1 and 3: A Multicentric Study From India

Priyanka Madhav Kambli<sup>1</sup>, Umair Ahmed Bargir<sup>1</sup>, Reetika Malik Yadav<sup>1</sup>, Maya Ravishankar Gupta<sup>1</sup>, Aparna Dhondi Dalvi<sup>1</sup>, Gouri Hule<sup>1</sup>, Madhura Kelkar<sup>1</sup>, Sneha Sawant-Desai<sup>1</sup>, Priyanka Setia<sup>1</sup>, Neha Jodhawat<sup>1</sup>, Nayana Nambiar<sup>1</sup>, Amruta Dhawale<sup>1</sup>, Pallavi Gaikwad<sup>1</sup>, Shweta Shinde<sup>1</sup>, Prasad Taur<sup>2</sup>, Vijaya Gowri<sup>2</sup>, Ambreen Pandrowala<sup>3</sup>, Anju Gupta<sup>4</sup>, Vibhu Joshi<sup>4</sup>, Madhubala Sharma<sup>4</sup>, Kanika Arora<sup>4</sup>, Rakesh Kumar Pilania<sup>4</sup>, Himanshi Chaudhary<sup>4</sup>, Amita Agarwal<sup>5</sup>, Shobita Katiyar<sup>5</sup>, Sagar Bhattad<sup>6</sup>, Stalin Ramprakash<sup>7</sup>, Raghuram Cp<sup>7</sup>, Ananthvikas Jayaram<sup>8</sup>, Vinod Gornale<sup>9</sup>, Revathi Raj<sup>10</sup>, Ramya Uppuluri<sup>10</sup>, Meena Sivasankaran<sup>11</sup>, Deenadayalan Munirathnam<sup>11</sup>, Harsha Prasad Lashkari<sup>12</sup>, Manas Kalra<sup>13</sup>, Anupam Sachdeva<sup>13</sup>, Avinash Sharma<sup>14</sup>, Sarath Balaji<sup>15</sup>, Geeta Madathil Govindraj<sup>16</sup>, Sunil Karande<sup>17</sup>, Ruchi Nanavati<sup>18</sup>, Mamta Manglani<sup>19</sup>, Girish Subramanyam<sup>20</sup>, Abhilasha Sampagar<sup>21</sup>, Indumathi Ck<sup>22</sup>, Parinitha Gutha<sup>23</sup>, Swati Kanakia<sup>24</sup>, Shiv Prasad Mundada<sup>25</sup>, Vidya Krishna<sup>26</sup>, Sheela Nampoothiri<sup>27</sup>, Sandeep Nemani<sup>28</sup>, Amit Rawat<sup>4</sup>, Mukesh Desai<sup>2</sup>, Manisha Madkaikar<sup>1</sup>

- Umbilical cord related complications like omphalitis (64%) and delayed cord separation (62%) were the most common manifestations
- Pneumonia 41%; sepsis 37%
- Perianal region was the commonest site for skin ulcers (27%)

**Infectious organisms were isolated from 69/106 cases:**

### Bacteria:

- *Pseudomonas aeruginosa* (n=28)
- *Staphylococcus aureus* (n=17)
- *Klebsiella pneumoniae* (n=11)
- Fungal infections (n=7)
- Unusual organisms included: ***Proteus sp.*, *Citrobacter sp.*, *Stingomonas paucimobilis*, and *Acinetobacter baumannii***

Case Reports > [Pediatr Dermatol. 2023 Dec 27. doi: 10.1111/pde.15492. Online ahead of print.](#)

## Extensive perineal ecthyma gangrenosum in leukocyte adhesion deficiency type 1 associated with *Staphylococcus hominis* bacteremia

Balamurugan Kalyanaprabhakaran<sup>1</sup>, Venkataraman Ranjith Kumar<sup>1</sup>,  
Jaikumar Govindaswamy Ramamoorthy<sup>1</sup>, Pediredla Karunakar<sup>1</sup>, Dhandapany Gunasekaran<sup>1</sup>,  
Bibekanand Jindal<sup>2</sup>

Case Reports > [J Clin Immunol. 2016 Oct;36\(7\):624-6. doi: 10.1007/s10875-016-0315-0.](#)

Epub 2016 Jul 15.

## Brain Abscess in a Child with Leukocyte Adhesion Defect: An Unusual Association

Ankur Kumar<sup>1</sup>, Aman Gupta<sup>1</sup>, Amit Rawat<sup>2</sup>, Chirag Ahuja<sup>3</sup>, Deepti Suri<sup>1</sup>, Surjit Singh<sup>1</sup>

Affiliations + expand

*Pseudomonas aeruginosa*

PMID: 27422622 DOI: [10.1007/s10875-016-0315-0](#)

Case Reports > [J Allergy Clin Immunol Pract. 2022 Sep;10\(9\):2448-2449.](#)

doi: [10.1016/j.jaip.2022.06.019](#). Epub 2022 Jul 15.

## Healing With Complication: An Unusual Case of Nasal Tip Ulceration in Leukocyte Adhesion Deficiency Type 1

*Pseudomonas aeruginosa*


Archan Sil<sup>1</sup>, Ridhima Aggarwal<sup>1</sup>, Sivanesan S<sup>1</sup>, Saniya Sharma<sup>1</sup>, Pandiarajan Vignesh<sup>2</sup>,  
Amit Rawat<sup>1</sup>

Case Reports > [J Pediatr Hematol Oncol. 2013 Aug;35\(6\):468-9.](#)

doi: [10.1097/MPH.0b013e31827e57b2](#).

## Congenital CMV with LAD type 1 and NK cell deficiency

Narendra Rai<sup>1</sup>, Neha Thakur



# Hyper-IgM syndrome

## Clinical and molecular features of X-linked hyper IgM syndrome – An experience from North India

Amit Rawat <sup>1</sup>, Babu Mathew <sup>1</sup>, Vignesh Pandiarajan <sup>1</sup>, Ankur Jindal <sup>1</sup>, Madhubala Sharma <sup>1</sup>,  
Deepti Suri <sup>1</sup>, Anju Gupta <sup>1</sup>, Shubham Goel <sup>2</sup>, Adil Karim <sup>2</sup>, Biman Saikia <sup>2</sup>, Ranjana W Minz <sup>2</sup>,  
Kohsuke Imai <sup>3</sup>, Shigeaki Nonoyama <sup>4</sup>, Osamu Ohara <sup>5</sup>, Silvia Clara Giliani <sup>6</sup>, Luigi D Notarangelo <sup>7</sup>,  
Koon-Wing Chan <sup>8</sup>, Yu-Lung Lau <sup>9</sup>, Surjit Singh <sup>10</sup>

- **Recurrent sinopulmonary infections noted in 8/10 children**
- **Infectious organisms isolated included:**

**Pneumocystis jiroveci (n=2), Klebsiella pneumoniae (n=2),**

**Mycobacterium tuberculosis (n=1), Clostridium difficile (n=1)**

# Anti-interferon- $\gamma$ autoantibody immunodeficiency




**Steven Holland**

# Adult-onset immunodeficiency in Thailand and Taiwan

N=97

Sarah K Browne<sup>1</sup>, Peter D Burbelo, Ploenchon Chetchotisakd, Yupin Suputtamongkol, Sasisopin Kiertiburanakul, Pamela A Shaw, Jennifer L Kirk, Kamonwan Jutivorakool, Rifat Zaman, Li Ding, Amy P Hsu, Smita Y Patel, Kenneth N Olivier, Viraphong Lulitanond, Piroon Mootsikapun, Siriluck Anunnatsiri, Nasikarn Angkasekwina, Boonmee Sathapatayavongs, Po-Ren Hsueh, Chi-Chang Shieh, Margaret R Brown, Wanna Thongnoppakhun, Reginald Claypool, Elizabeth P Sampaio, Charin Thepthai, Duangdao Waywa, Camilla Dacombe, Yona Reizes, Adrian M Zelazny, Paul Saleeb, Lindsey B Rosen, Allen Mo, Michael Iadarola, Steven M Holland



- **Mycobacteria**

Rapidly growing	75
Slowly growing	23
Nontuberculous mycobacteria	7
Mycobacterium tuberculosis	14

- **Varicella–zoster virus**

Disseminated	3
Localized	15

- **Bacteria**

Salmonella sp.	25
Burkholderia pseudomallei	4

- **Fungi**

Cryptococcus neoformans	10
Histoplasma capsulatum	7
Penicillium marneffe	7

Autoantibody to Interferon-gamma Associated with Adult-Onset Immunodeficiency in Non-HIV Individuals in Northern Thailand

[Panuwat Wongkulab](#), <sup>1</sup> [Jiraprapa Wipasa](#), <sup>2</sup> [Romanee Chaiwarith](#), <sup>1</sup> and [Khuanchai Supparatpinyo](#) <sup>1, 2, \*</sup>

- **Opportunistic infections among 20 cases included:** disseminated NTM infection (19 patients/24 episodes), disseminated Penicilliosis marneffei (12 patients/12 episodes), and non-typhoidal Salmonella bacteremia (7 patients/8 episodes)
- Level of antibody to IFN-γ in patients who had active opportunistic infection was relatively higher than in those without active infection

an IPOPI event	
Opportunistic infections <sup>+</sup>	Cases (N=20)
Infections caused by non-tuberculous mycobacteria	24
Rapid-grower mycobacteria	11
<i>M. chelonae</i>	3
<i>M. abscessus</i>	4
<i>M. chelonae-abscessus complex</i>	3
<i>M. fortuitum</i>	1
Slow grower mycobacteria	7
<i>M. avium</i>	3
<i>M. avium/paratuberculosis/solitarium</i>	1
<i>M. kansasii</i>	3
Species not specified	6
Penicilliosis marneffei	12
Cryptococcosis	1
Histoplasmosis	1

# Infections in PID patients in the Asia Pacific region

Breakthrough infections are more common

Profile is different

Polymicrobial infections may be more common


Facilities for isolating the causative organism may not be adequate

**Threshold for starting antimicrobials is much lower**

**Clinical decisions need to be based on local experience**



***Acknowledgements***



# Q&A



**IPOPI**  
**5<sup>TH</sup> REGIONAL**  
**ASIAN PID MEETING**  
24-25 MARCH 2024  
TOKYO, JAPAN  
an **IPOPI** event

#### COLLABORATION



#### SUPPORTED BY



**IPOPI**  
IPOPI.ORG

# Flow Cytometry for Diagnostics: Value, Context, and Sustainability

Dr Jaime Sou da Rosa Duque | Hong Kong



IPOPI  
5<sup>TH</sup> REGIONAL  
ASIAN PID MEETING  
24-25 MARCH 2024  
TOKYO, JAPAN  
an IPOPI event

#### COLLABORATION



#### SUPPORTED BY



# Jaime Rosa Duque, MD, PhD, FHKAM (Paed), FAAP, FAAAAI

Presenter

**Clinical Assistant Professor**  
*The University of Hong Kong*



**HKU  
Med**

School of Clinical Medicine  
Department of Paediatrics  
& Adolescent Medicine  
香港大學兒童及青少年科學系

**Honorary Distinguished Professor**  
**Immunology and Rheumatology**  
*Guangzhou Women and Children's  
Medical Center*



**IPOPI  
5<sup>TH</sup> REGIONAL  
ASIAN PID MEETING**  
24-25 MARCH 2024  
TOKYO, JAPAN  
an IPOPI event

COLLABORATION



SUPPORTED BY




GRIFOLS

# Flow Cytometry for Diagnostics: Value, Context, and Sustainability


# Introduction to Flow Cytometry

- a precise technique for measurement of multiple characteristics of individual cells within heterogeneous populations





# Introduction to Flow Cytometry

- a precise technique for measurement of multiple characteristics of individual cells within heterogeneous populations
- consists of five main components:
  - a flow cell (through which cells flow)
  - a laser
  - optical components
  - detectors to amplify signals
  - electronics/computer system




# Introduction to Flow Cytometry

- although peripheral blood is the most common and normal ranges have been better delineated, any biologic sample (peripheral blood, bone marrow, CSF, BAL) can be analyzed




# Introduction to Flow Cytometry

- any suspended cell or particle ranging from 0.2 to 150 micrometers in size is suitable for analysis




# Introduction to Flow Cytometry

- any suspended cell or particle ranging from 0.2 to 150 micrometers in size is suitable for analysis




# Introduction to Flow Cytometry

- any suspended cell or particle ranging from 0.2 to 150 micrometers in size is suitable for analysis





- analyses to determine cellular characteristics: size, granularity, viability, and immunophenotyping, which are the most common types of studies


## Parameters



# Parameters





# Parameters




# Immunophenotyping

- a technique used to characterize the makeup of cell populations by detecting cellular protein expression




# Immunophenotyping

- a technique used to characterize the makeup of cell populations by detecting cellular protein expression
- uses an antibody specific for the antigen of interest that is conjugated to a fluorescent compound known as a fluorophore or fluorochrome




# Immunophenotyping

- a technique used to characterize the makeup of cell populations by detecting cellular protein expression
- uses an antibody specific for the antigen of interest that is conjugated to a fluorescent compound known as a fluorophore or fluorochrome
- the fluorescent compounds absorb energy from the laser source, causing an electron to be raised to a higher energy level




# Immunophenotyping

- a technique used to characterize the makeup of cell populations by detecting cellular protein expression
- uses an antibody specific for the antigen of interest that is conjugated to a fluorescent compound known as a fluorophore or fluorochrome
- the fluorescent compounds absorb energy from the laser source, causing an electron to be raised to a higher energy level
- the excited electron quickly returns to its ground state, emitting the excess energy as a photon of light of a characteristic wavelength that is detected by the flow cytometer



# Immunophenotyping

- a technique used to characterize the makeup of cell populations by detecting cellular protein expression
- uses an antibody specific for the antigen of interest that is conjugated to a fluorescent compound known as a fluorophore or fluorochrome
- the fluorescent compounds absorb energy from the laser source, causing an electron to be raised to a higher energy level
- the excited electron quickly returns to its ground state, emitting the excess energy as a photon of light of a characteristic wavelength that is detected by the flow cytometer
- different fluorochromes are excited by different wavelengths of light and emit light at different wavelengths





# Immunophenotyping

- the intensity of light emitted by each fluorochrome reflects the level of expression of the antigen of interest



Fluorophore



A




B



# Conventional vs Spectral Flow Cytometry

## Conventional Flow Cytometry

- most conventional flow cytometry in clinical use consist of 10 to 12 different markers with separate detectors





# Conventional vs Spectral Flow Cytometry

## Conventional Flow Cytometry

- most conventional flow cytometry in clinical use consist of 10 to 12 different markers with separate detectors


## Spectral Flow Cytometry

- similar to conventional flow cytometry but with multiple detectors for each fluorochrome rather than one detector
- this allows for better differentiation of fluorochromes based upon the fluorescent spectral signature of each fluorochrome, enabling the use of more fluorochromes in a single sample
- some can resolve 40 different fluorochromes in one sample




# Mass Cytometry or Cytometry by Time-of-flight (CyTOF)



- technology that combines flow cytometry with mass spectrometry
- antibodies labeled with heavy-metal ions
- readout is based on the atomic number of the heavy metal, and there is little overlap between the isotopes
- a greater number of antibodies can be used simultaneously, allowing for analysis of over 40 targets per cell
- not widely available clinically but possibly become more prominent in the future



# Mass Cytometry or Cytometry by Time-of-flight (CyTOF)



# Mass Cytometry or Cytometry by Time-of-flight (CyTOF)



## Flow Cytometry for Diagnosis of IEL (routine)

- useful in determination of absence of specific leukocytes and lymphocyte subpopulations
- routine screening includes:

Cell Marker	Lymphocyte Subpopulation	Absence Suggests
CD3 <sup>+</sup>	T cells	SCID
CD4 <sup>+</sup>	T helper cells	SCID or HIV/AIDS
CD8 <sup>+</sup>	Cytotoxic T cells	SCID or CID
CD19 <sup>+</sup>	B cells	Agammaglobulinemia
CD16 <sup>+</sup> 56 <sup>+</sup>	Natural killer cells	Variable

## Flow Cytometry for Diagnosis of IEI (routine)

- useful in determination of absence of specific leukocytes and lymphocyte subpopulations
- routine screening includes:

Cell Marker	Lymphocyte Subpopulation	Absence Suggests
CD3 <sup>+</sup>	T cells	SCID
CD4 <sup>+</sup>	T helper cells	SCID or HIV/AIDS
CD8 <sup>+</sup>	Cytotoxic T cells	SCID or CID
CD19 <sup>+</sup>	B cells	Agammaglobulinemia
CD16 <sup>+</sup> 56 <sup>+</sup>	Natural killer cells	Variable
CD45RA <sup>+</sup>	Naïve T cells	SCID
CD45RO <sup>+</sup>	Memory T cells	Expected in newborns

# Flow Cytometry for Screening and Diagnosis of Severe Combined Immunodeficiencies (SCID)

**TABLE E8.** Lymphocyte phenotype classification of SCID

Disease	Genes	References
<b>T<sup>-</sup>B<sup>-</sup>NK<sup>-</sup></b>		
Adenosine deaminase	<i>ADA</i>	89, 90
Adenylate kinase (reticular dysgenesis)	<i>AK2</i>	91-93
<b>T<sup>-</sup>B<sup>-</sup>NK<sup>+</sup></b>		
Artemis	<i>DCLRE1C</i>	94, 95
Cernunnos	<i>NHEJ1</i>	96, 97
DNA-dependent protein kinase	<i>PRKDC</i>	98
DNA ligase IV	<i>LIG4</i>	99, 100
RAG1 and RAG2	<i>RAG1, RAG2</i>	101-104

**TABLE E8.** Lymphocyte phenotype classification of SCID


Disease	Genes	References
<b>T<sup>-</sup>B<sup>+</sup>NK<sup>-</sup></b>		
X-linked SCID	<i>IL2RG</i>	67, 105-108
JAK3 deficiency	<i>JAK3</i>	106, 109
CD25 deficiency	<i>IL2RA</i>	110, 111
<b>T<sup>-</sup>B<sup>+</sup>NK<sup>+</sup></b>		
CD3 complex defects	<i>CD3D, CD3E, CD3Z</i>	112-115
Coronin 1A deficiency	<i>CORO1A</i>	88
CD45 deficiency	<i>PTPRC</i>	116, 117
IL-7 receptor deficiency	<i>IL7RA</i>	115, 118

# Flow Cytometry for Diagnosis of IEI (XLA)

Bruton's  
agammaglobulinemia


## X-LINKED AGAMMAGLOBULINEMIA

\* X-LINKED RECESSIVE \*  
genetic condition



## Flow Cytometry for Diagnosis of IEI (XLA)


- useful in determination of absence of specific leukocytes and lymphocyte subpopulations
- routine screening includes:



Cell Marker	Lymphocyte Subpopulation	Absence Suggests
CD3 <sup>+</sup>	T cells	SCID
CD4 <sup>+</sup>	T helper cells	SCID or HIV/AIDS
CD8 <sup>+</sup>	Cytotoxic T cells	SCID or CID
CD19 <sup>+</sup>	B cells	Agammaglobulinemia
CD16 <sup>+</sup> 56 <sup>+</sup>	Natural killer cells	Variable
CD45RA <sup>+</sup>	Naïve T cells	SCID
CD45RO <sup>+</sup>	Memory T cells	Expected in newborns



# Flow Cytometry for Diagnosis of IEI (XLA)

Bruton's  
agammaglobulinemia



# Flow Cytometry for Diagnosis of IEI (XLA)



Bruton's  
agammaglobulinemia



# Flow Cytometry for Diagnosis of IEI (XLA)


Bruton's  
agammaglobulinemia

Mother



## Flow Cytometry for Diagnosis of IEI (Job's syndrome)

**Hyper IgE syndrome (Job's syndrome)**




**Job's syndrome is characterized by**


- Skin abscesses
- recurrent pneumonia
- eczema
- elevated levels of IgE, a
- facial abnormalities and bone fragility

**It's a inherited immunodeficiency disorder**



# Flow Cytometry for Diagnosis of IEI (Job's syndrome)





# Flow Cytometry for Diagnosis of IEI (Job's syndrome)




# Flow Cytometry for Diagnosis of IEI (Job's syndrome)




# Flow Cytometry for Diagnosis of IEI (CGD)




# Flow Cytometry for Diagnosis of IEI (CGD)




## Healthy




## Patient



# Flow Cytometry for Diagnosis of IEI (CGD)



DHR

7D5  
(gp91phox/p22phox)


## Flow Cytometry for Diagnosis of IEI (STAT1 GOF)




## Flow Cytometry for Diagnosis of IEI (STAT1 GOF)



Healthy





Patient




## Flow Cytometry for Diagnosis of IEI (STAT6 GOF)



# Flow Cytometry for Diagnosis of IEI (STAT6 GOF)



# Flow Cytometry for Diagnosis of IEI (STAT6 GOF)



# Flow Cytometry for Diagnosis of IEI (STAT6 GOF)



Jesse, maroon shirt in the middle, says he is finally able to do "normal" activities such as going out with friends (Photo and caption provided by B.C. Children's Hospital)





COLLABORATION



SUPPORTED BY



# Q&A



**IPOPI**  
**5<sup>TH</sup> REGIONAL**  
**ASIAN PID MEETING**  
24-25 MARCH 2024  
TOKYO, JAPAN  
an **IPOPI** event

#### COLLABORATION



#### SUPPORTED BY



**IPOPI**  
IPOPI.ORG

# Tailoring Newborn Screening for Severe Combined Immunodeficiency in Asian Context

Insights from Japan | Dr Manabu Wakamatsu (*Japan*)

Insights from Malaysia | Dr Adli Ali (*Malaysia*)



IPOPI  
5<sup>TH</sup> REGIONAL  
ASIAN PID MEETING  
24-25 MARCH 2024  
TOKYO, JAPAN  
an IPOPI event

COLLABORATION



SUPPORTED BY



# Tailoring Newborn Screening for Severe Combined Immunodeficiency in Asian Context: Insights from Japan

Department of Pediatrics, Nagoya University Graduate  
School of Medicine, Nagoya, Japan

Manabu Wakamatsu



# IPOPI 5th Regional Asian PID Patients and Doctors' Meeting

## COI Disclosure Information

*Presenter : Manabu Wakamatsu*


I have no financial relationships to disclose.

# Severe Combined ImmunoDeficiency (SCID)

The severe dysfunction of cellular and humoral immunity owing to impaired T/B cell development or function.

Without any treatment, SCID develop opportunistic and/or severe infections during infancy, leading to death.


A cohort of 181 SCID patients undergoing their first allogeneic HSCT in 1974–2016.



# National Landscape of the TREC Newborn Screening Programs

Prefectures conducting  
TREC NBS programs

**40/48 = 83%**



2017.4 : 愛知 Aichi

2019.2 : 熊本

2019.4 : CReARID (埼玉・千葉・群馬の一部など13自治体)

2020.4 : 宮崎

2020.5 : 千葉

2020.8 : 大阪市・大阪府

2020.11 : 北海道

2020.11 : 新潟

2021.1 : 宮城

2021.4 : 岐阜・兵庫・(佐賀：一部)

2021.5 : 島根

2021.10 : 愛媛

2022 : 栃木、茨城、神奈川、山形、広島、鹿児島、長崎、石川、長野


2023 : 佐賀、東京、福岡、秋田、岩手、福島、三重、香川、徳島、高知、福井、青森、静岡、滋賀、和歌山  
(準備中 : 11 : 埼玉、山梨、群馬、富山、京都、奈良、鳥取、岡山、山口、大分、沖縄)

公費化 : 5 : 熊本、栃木、佐賀、安曇野、高崎

# National Landscape of the TREC Newborn Screening Programs

Prefectures conducting  
TREC NBS programs

**40/48 = 83%**



2017.4 : 愛知 Aichi

2019.2 : 熊本

2019.4 : CReARID (埼玉・千葉・群馬の一部など13自治体)

2020.4 : 宮崎

2020.5 : 千葉

2020.8 : 大阪市・大阪府

2020.11 : 北海道

2020.11 : 新潟

2021.1 : 宮城

2021.4 : 岐阜・兵庫・(佐賀：一部)

2021.5 : 島根

2021.10 : 愛媛

2022 : 栃木、茨城、神奈川、山形、広島、鹿児島、長崎、石川、長野


2023 : 佐賀、東京、福岡、秋田、岩手、福島、三重、香川、徳島、高知、福井、青森、静岡、滋賀、和歌山  
(準備中 : 11 : 埼玉、山梨、群馬、富山、京都、奈良、鳥取、岡山、山口、大分、沖縄)

公費化 : 5 : 熊本、栃木、佐賀、安曇野、高崎

# National Landscape of the TREC Newborn Screening Programs

Prefectures conducting  
TREC NBS programs

**40/48 = 83%**




## Aichi Prefecture

- Nagoya is the capital of Aichi Prefecture, and the fourth-largest city in Japan.
- A population of 7.5 million.
- 40,000-50,000 newborns per year.



**Nagoya Castle**

# Organization of TREC/KREC NBS program in Aichi Prefecture




# Results of TREC/KREC NBS program in Aichi Prefecture

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

■ NBS programs at **full public expenditure** (n)  
■ TREC/KREC NBS program (n)


A total of 204,247 measurements of TREC and/or KREC between 2017 and 2023




# Rates of retest and detailed examination

Retest ; measurement of TREC/KREC using other DBSs.

Detailed examination ; retests also had abnormal values, and NGS and FCM analysis were performed.



[illegible]

IPOPI.org

# Definitions of terms related to the TREC/KREC NBS programs

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

Uniformity of terminology in the TREC/KREC NBS programs is proposed.


NBS for SCID-specific definition	Terminology used in screening programs	Recommendations in this publication
<div>(Opt.:) Absent/very low TRECs without DNA amplification failure</div> <div>Below TREC cut-off without DNA amplification failure</div>	<div>Screen positive, positive NBS SCID screen, abnormal, presumptive positive, borderline positive, equivocal, positive, urgent positive, screening positive, positive detection, abnormal TREC screen, initial positives, true positives, TREC/KREC negative, pathological results, positive SCID NBS report</div>	<div>Urgent Abnormal value</div> <div>Abnormal value</div>
<div>Above TREC cut-off</div>	<div>Normal, negative, normalized, negative detection, negative NBS result, TREC/KREC positive, TREC/KREC weak positive, real TREC negative, screen negative, negative SCID NBS report</div>	<div>Normal value</div>
<div>DNA amplification failure</div>	<div>Indeterminate, inconclusive, incomplete, DNA amplification failure (DAF), inadequate, invalid result, unsatisfactory SCID NBS report</div>	<div>Incomplete</div>
<div>Repeated TREC analysis on the same NBS card (not going back to the newborn)</div>	<div>Repeated testing, retest, rerun, repeat testing, reanalysis, second analysis, repeated TREC analysis, second punch analyzed, second run</div>	<div>Retest</div>
<div>A new sample is requested and analyzed with TREC-assay (going back to the newborn)</div>	<div>Second sample, second DBS, second NBS sample, repeated filter card sample, second Guthrie card, new sample, resampling, repeat DBS, 2nd DBS request, repeat NBS, repeated TREC testing on second DBS, repeat heel prick, new NBS card, repeat NBS specimen</div>	<div>New sample test</div>
<div>A newborn is referred for follow-up diagnostics to a pediatrician</div>	<div>Recall, referral, positive detection, callback, follow-up</div>	<div>Referral</div>

# EnLite™ Neonatal TREC vs. TREC/KREC Kits



IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event

## EnLite™ Neonatal TREC



## EnLite™ Neonatal TREC/KREC




# TREC NBS program (2017/4/1~2020/3/31)

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event

NGS; next-generation sequencing  
FCM; flow cytometry




# TREC NBS program (2017/4/1~2020/3/31)

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event

NGS; next-generation sequencing  
FCM; flow cytometry




# TREC · KREC NBS programs (2020/4/1 ~ 2023/11/30)

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event

NGS; next-generation sequencing  
FCM; flow cytometry




# TREC · KREC NBS programs (2020/4/1 ~ 2023/11/30)

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event

NGS; next-generation sequencing  
FCM; flow cytometry




# TREC · KREC NBS programs (2020/4/1 ~ 2023/11/30)

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event

NGS; next-generation sequencing  
FCM; flow cytometry




# TREC · KREC NBS programs (2020/4/1 ~ 2023/11/30)

IPOPI 5<sup>TH</sup> REGIONAL ASIAN PID MEETING

an IPOPI event


NGS; next-generation sequencing  
FCM; flow cytometry



# FOXN1-SCID

In 2019, 21 newborns with low TREC and T-cell lymphopenia and heterozygous *FOXN1* variants were initially reported.

FOXN1 is the causative gene in nude mice and is a transcription factor essential for thymic epithelial progenitor cells to initiate T cell differentiation and maturation.



# Non-SCID with low T-cell counts identified by TREC NBS programs

Combined immunodeficiency, including single-gene and syndromic disorders of T-cell development, such as the following:

- Ataxia-telangiectasia
- Disorders of folate absorption or metabolism
- MHC class I and II defects
- Nijmegen breakage syndrome
- Trisomy 21 and other chromosomal aneuploidies

Disorders of thymic stromal cell development, such as the following:

- CHARGE syndrome
- DiGeorge syndrome (complete or partial)
- Other disorders of thymic stromal cell development (eg, pathogenic variants in genes such as *FOXN1*, *FOXI3*, *TBX1*, *TBX2*, *CHD7*, or *PAX1*)

Idiopathic T-cell lymphopenia

Secondary T-cell lymphopenia due to:

- Advanced *in utero* HIV infection
- Chylous effusions, spontaneous or postsurgery
- Gastrointestinal or cardiac malformations
- Hydrops
- Maternal immunosuppressive medications
- Preterm birth, very low birth weight

*Dvorak CC, et al. JACI. 2023.*

In Aichi Prefecture, TREC/KREC NBS programs have been performed for more than 200,000 newborns to date.

TREC/KREC NBS programs are further expected to be expanded as a publicly funded screening test in Japan.

SCIDs should be promptly referred to a hospital for the detailed examination, and prepared for the prevention of infection and appropriate therapeutic intervention.

The development of management frameworks and specific guidelines regarding follow-up for Non-SCID PIDs is a challenge to be addressed in the future.

Patients and family members

Department of Pediatrics, Nagoya University  
Graduate School of Medicine, Nagoya, Japan.

Nobuhiro Nishio, Atsushi Narita, Kotaro Narita,  
Ayako Yamamori, Yusuke Tsumura, Ryo Maemura,  
Sajiki Daichi, Yamashita Daiki



# TAILORING NBS FOR SCID IN ASIA: INSIGHT FROM MALAYSIA

---

Presenter

**Associate Professor Dr Adli Ali**  
Consultant Pediatric Immunologist  
Universiti Kebangsaan Malaysia



**IPOPI  
5<sup>TH</sup> REGIONAL  
ASIAN PID MEETING**  
24-25 MARCH 2024  
TOKYO, JAPAN  
an IPOPI event

COLLABORATION



SUPPORTED BY




GRIFOLS

# WHAT IS SCID AND WHY?

- Severe Combined Immunodeficiency (SCID)
  - absence of both cellular and humoral immunity
    - 30 different genes known to cause SCID
  - profound defects in T lymphocyte
- Affected infants develop infections (SPUR)
  - Recurrent infections, chronic diarrhea, sepsis, FTT
  - Death usually before 1 year of age
  - Treatment/ prevention of infections- not curative
- Curative-HSCT/ gene therapy
  - Preferably before the onset of infections
  - Preferably before 3.5 months


Age at Transplantation and Infection Status




# WHY SCID IS A PERFECT “NBS” MODEL DISEASE?

## THE SCIENTIFIC ANGLE

- Different gene mutations causing SCID
  - with around 25% yet to be known mutation
- Nearly all SCID- absent/ non-functional T- cells
  - The unique position of *TREC*
- What is *T-cell receptor excision circles (TREC)* ?
- By-products of TCR genes during thymocyte maturation
  - Episomal DNA → do not replicate during mitosis
- detected in peripheral blood by quantitative PCR
  - correlate with numbers of naïve T-cells
  - Low TREC levels → SCID, DiGeorge syndrome, congenital lymphopenia





# TREC quantification

# WHY SCID IS A PERFECT “NBS” MODEL DISEASE?

## PUBLIC HEALTH ANGLE

Prevalence of the disease 1:100,000 or greater  
SCID: 1:50,000-1:100,000

Can the disorder be detected by routine physical exam?  
SCID: Baby appears normal at birth.


Does the disease cause serious medical complications?  
SCID: 100% fatal within the first year of life

Is there a cheap, sensitive and specific screening test?  
SCID: Real time PCR to enumerate T cell receptor excision circles

Is there a confirmatory test?  
SCID: Lymphocyte subpopulation analysis

Does early detection improve outcome?  
SCID: Early HSCT decreases mortality from SCID

# SCID Newborn Screening in Malaysia: The Initial Phase



## 'Bubble girl' Marissa Hani dies

Bernama  
Published: Aug 14, 2015 4:21 PM · Updated: 5:16 PM

Marissa Hani Mohammed Zubir, aged two, who suffered from Severe Combined Immunodeficiency Disease (SCID) or better known as 'bubble boy disease' passed away 47 days after being admitted to the Serdang Hospital intensive care unit (ICU).

Marissa, the first child in Malaysia to have successfully undergone a bone marrow transplant last year in which the donor was her own mother, Nazellyn, died in the hospital at 2.26 pm yesterday from severe ventriculitis with hydrocephalus (compressing of the brain stem due to SCID).

# SCID NEWBORN SCREENING IN MALAYSIA: THE INCUBATION PHASE

Enhancing ecosystem: Strengthening expertise in curative management

Establishing Database : real-national data of SCID

Observation: Experiences from other countries

Capacity Building: Learning and understanding the technology

Pondering : The need, the feasibility in Malaysia

RESEARCH

Open Access



# The PID Life Index: an interactive tool to measure the status of the PID healthcare environment in any given country

Leire Solís<sup>1</sup>, Julia Nordin<sup>1</sup>, Johan Prevot<sup>1</sup>, Nizar Mahlaoui<sup>2,3</sup>, Silvia Sánchez-Ramón<sup>4,5</sup>, Adli Ali<sup>6,7</sup>, Elodie Cassignol<sup>8</sup>, John W. Seymour<sup>1,9</sup> and Martine Pergent<sup>1\*</sup> 

# PID Treatment:


## Curative treatment (BMT/ HSCT)



### **Bone marrow transplantation or haematopoietic progenitor cell transplantation**

Specialised treatments in which HSC of an HLA compatible donor are provided to patients with usually severe PIDs (SCID, severe CGD) when the immune cells are missing or malfunctioning.

- **Gene Therapy**
- **Thymic Transplant**



# SCID STATUS IN MALAYSIA: DATA


- Before 2014
  - all the 16 diagnosed cases- died (Mortality is 100%)
  - Many underdiagnosed/ misdiagnosed
  - Lack of awareness/ inability to provide appropriate test/ no treatment
- After 2014
  - Cases diagnosed increased 3-4 cases per year (better awareness, faster accurate diagnosis, treatment)
  - Survival is 85% (15% because of delayed diagnosis)
- In 2023 (Collective data from Assoc. Prof. Dr. Intan Hakimah and Dr Intan Juliana )
  - 5 cases in 2023 (with 2 suspected SCID-presented to late for diagnosis)
  - Estimated if universal data (1:58000 – should be 10 cases)
    - If following latest Singapore based estimation (1: 20000)- missed 22 cases (diagnosing 18%)

# Real apac experience: NBS FOR SCID IN SINGAPORE

- TREC assay : 10 October 2019 to 9 October 2020
- using the Enlite Neonatal TREC kit.
- 35888 newborns screened in 1 year
- no SCID cases were detected
- 13 cases of non-SCID T-cell lymphopenia (TCL)
- Retest rate was 0.1%
- Referral rate to immunologist was 0.04%.
- Latest update in 2023
- 2 cases of SCID ( 38,000 live birth in 2022)
- Incidence of 1: 18000
- If Malaysia: 27-28 cases/ year (500,000 live birth)

Severe Combined Immunodeficiency Newborn Screening in Southeast Asia :  
Outlook from SEAPID consortium,

Wai Leng Chang, Adli Ali et al, Under Review, 2024



# Newborn Screening for SCID in Malaysia:

## Determining the needs:

Survey, Pilot Project, Expert Discussion

## Evaluating the technology:

Private-Clinician Partnership (Revvity-Arcadia Life Sciences- HPKK)

## Partners Engagement:

IPOPI, Other NGO, MOH, MOHE, Pharma, Tech Provider

## Advocacy:

WPIW campaign, Whitepaper, Screen4Rare

## Feasibility and the cost-benefit analyses:

Framework and Pilot evaluation

# OUTLOOK OF SCID NBS IN MALAYSIA:

## ADVOCACY: WPIW, WHITEPAPER, INTERNATIONAL OUTREACH




Time	Presentation	Speaker
3rd Session: PID diagnostics in Asia Moderator: Martine Pergent		
09:00	Opening remarks	Martine Pergent IPOPI Chair
09:10	Keynote Opening Lecture: State of the art of PID diagnosis in Asia	Dr Narissara Suratannon, Chulalongkorn University Hospital
09:30	Cytokine auto-antibodies: from regulation to disease	Dr Wim Dik
09:45	IPOPI PIDetect programme: Bangladesh/India	TBC
09:55	Newborn screening for rare diseases – real life experiences and future opportunities	Dr Nizar Mahlaoui, country experience from France (10 min)  Dr Adli Ali, Screen4Rare & Malaysia (10 min)
10:15	Questions & Answers	ALL
10:35	COFFEE BREAK	




# OUTLOOK OF SCID NBS in MALAYSIA: determining the needs: Experts' opinion

Possibility of SCID Newborn Screening Implementation



Strategies to be Employed in Implementing SCID Newborn Screening





OUTLOOK OF SCID NBS in  
MALAYSIA:  
screen4rare, industry-clinician  
partnership





OUTLOOK OF SCID NBS IN MALAYSIA:  
PARTNERS ENGAGEMENT (MOHE-MOH-NGO-  
PHARMA)

# FUTURE OUTLOOK

## ❖ **NBS for SCID in developing nation: Malaysia and SEA**

- ❖ Understanding why, when, and how
- ❖ The pre-requisite ecosystem

## ❖ **Importance of understanding local context**

- ❖ Knowing the disease burden and management
- ❖ Identifying the stakeholders and the game changer
- ❖ Framing a practical roadmap

## ❖ **Potential interesting date to observe: 28<sup>th</sup> June 2024**

# COFFEE BREAK

## 15 MIN

### COLLABORATION



### SUPPORTED BY

